Introduction

19
Milk proteins contain specific peptide motifs, termed bioactive peptides (BAPs), which have 20 been identified in vitro for their potential role in beneficially modulating specific biomarkers of 21 health. To date, several dietary intervention studies have been conducted to investigate the effect 22 of milk protein-derived peptides in human health [3, 7, 16] . While some studies have demon-23 strated a positive role of milk protein-derived BAPs in humans, other studies have failed to iden-24 tify an improvement in specific health biomarkers following the consumption of BAPs or intact 25 milk proteins [31, 32] . 26
The rate of discovery of peptide sequences originating from dietary proteins which display in 27 vitro bioactive properties has increased over the past number of years. This has been made possi-28 ble notably with advances in chromatographic separation techniques coupled with mass spectro-29 metric detection of peptides [36] . In addition, quantitative structure activity relationship (QSAR) 30 studies have allowed the development of a more in-depth understanding of BAP sequences [11, 31 13, 34, 39] . QSAR generally consists in the analysis of multivariate peptide descriptors which 32 are linked to biological activity using computational methods such as partial least square regres-33 sion (PLSR), multiple linear regression (MLR), principal component analysis (PCA) or artificial 34 neural networks (ANN) [10, 11] . QSAR has been applied in the study of The main advantage of using QSAR approaches over qualitative assessment of peptides to study 38 their bioactive properties is that QSAR may provide a means to predict the potency of specific 39 peptide sequences. While several bioactive properties have been studied using QSAR, others do 40 not appear, to date, to have been assessed with this approach. As already indicated, QSAR has 41 been applied to different BAPs, however, to date, it does not appear to have been applied to di-42 peptidyl peptidase IV (DPP-IV) inhibitory sequences. DPP-IV is an amino dipeptidyl peptidase 43 which hydrolyses and inactivates the incretin hormones glucose dependent insulinotropic poly-44 peptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Inhibition of DPP-IV 45 can prevent incretin degradation, allowing maintenance of their insulinotropic activity during the 46 post-prandial phase [6] . While DPP-IV inhibitory drugs (i.e., gliptins) are currently used for the 47 treatment of type 2 diabetes (T2D), there is also a growing interest in employing naturally de-48 rived compounds such as dietary peptides for their DPP-IV inhibitory properties [12, 33] . In this 49 context, several studies have shown that milk protein-derived peptides can inhibit DPP-IV in 50 vitro [17, 25, 42, 47] . 51
The antidiabetic properties of intact and hydrolyzed milk proteins has been reported in the litera-52 ture [31, 32] . Numerous milk protein-derived peptides have been identified in the intestinal tract 53 of humans following the ingestion of milk and dairy products [1, 2, 34]. However, the contribu-54 tion of these peptides to human health is still unknown [32] . In vivo studies demonstrating the 55 antidiabetic effect of milk protein-derived DPP-IV inhibitory peptides have been conducted in 56 small animals [48, 49] . To our knowledge, no studies to date have reported that milk protein-57 derived peptides present within the intestinal tract of humans could act as DPP-IV inhibitors. 58 Therefore, the aim of this study was to demonstrate that peptides which may be released during 59
DPP-IV inhibition assay and mode of inhibition 76
The DPP-IV inhibition assay was conducted as described by Nongonierma and FitzGerald [25] . 77
The peptides were tested in the concentration range of 12.5 × 10 -3 to 1.25 mg mL -1 (final concen-78 tration). Each sample was analyzed in triplicate (n=3). The DPP-IV half maximal inhibitory con-79 centrations (IC 50 ) were determined by plotting the percentage inhibition as a function of the con-80 centration of test compound using a logistic regression. 81
The mode of DPP-IV inhibition was assessed using the Lineweaver and Burk double reciprocal 82 representation as previously described by Nongonierma and FitzGerald [25] . The peptides were 83 evaluated at two concentrations, i.e., their IC 50 values divided by 8 and 40. The concentrations of 84 GP-pNA ranged from 0.1 to 0.5 mM (final concentration). These substrate concentrations were 85 selected as they were consistent with the limits of detection for pNA and allowed the obtention 86 of a linear response for the Lineweaver and Burk double reciprocal analysis 87
QSAR of DPP-IV inhibitory peptides 88
The QSAR model was developed as a tool to predict the DPP-IV inhibitory potency of unknown 89 peptides, i.e., peptides specifically reported to be present in the intestinal tract following inges-90 tion of milk/dairy products. All IC 50 values were obtained with the same assay as previously de-91 scribed for the determination of DPP-IV inhibition [25] . The peptides used to build the QSAR 92 model consisted of competitive DPP-IV inhibitors which had been identified in previous studies 93 (Table 1) to 5 amino acid residues. Therefore, the peptide descriptors were generated using a method al-101 lowing data treatment for peptides with various lengths as described by Li and Li [19] . The two 102 N-and C-terminal amino acids of the peptides were used to generate the peptide descriptors. (Table 1) . Of these peptides, one (IPPL, Figure 1A ) was uncompeti-140 tive, two (FP and HP, Figure 1B) were mixed-type, one (LPP, Figure 1C (Table 1) . 148
All the DPP-IV IC 50 values used to build the QSAR model were obtained using the same exper-149 imental conditions [25] . Furthermore, the peptides included in the QSAR dataset only consisted 150 of the competitive DPP-IV inhibitory peptides (26) as outlined in Table 1 . 151
QSAR models 152
The two QSAR models linking the DPP-IV IC 50 value to the peptide descriptors were significant, 153 having a p of 0.00279 and 0.00437 for the z-and v-scale models, respectively ( Table 2) The parameters of the PLSR for the two QSAR models developed with the two scales for amino 158 acid descriptors are shown in Table 3 . For the QSAR model developed with the z-scale, the two 159 coefficients linked with the hydrophilicity of the N 1 ( 1,1 ) and N 2 ( 2,1 ) terminal amino acids 160 were significant (p < 0.05). The positive value of these coefficients suggested that a reduced hy-161 drophilicity for the two N terminal amino acids would decrease the DPP-IV IC 50 value (i.e., in-162 crease the potency). In the case of the v-scale model, only the coefficient linked with the hydro-163 phobicity of the N 1 ( 1,3 ) terminal amino acid was significant (p < 0.05). It was negatively corre-164 lated to the DPP-IV IC 50 value, suggesting that hydrophobic amino acids located at the N-165 terminus of the peptides would tend to decrease the DPP-IV IC 50 value. While both QSAR mod-166 els resulted in different outcomes, they both predicted that the hydrophobicity of the N-terminal 167 amino acid plays a significant role in DPP-IV inhibitory potency. Table S1 ). 176
The two QSAR models (Table 3) were used to predict the DPP-IV IC 50 values of the 56 peptides 177 (Table 4 and Supplementary Table S1) (Table 4 and Supplementary Table S1 ). In addition, both models Table captions   Table 1 . Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC 50 ) and mode of inhibition of milk protein-derived peptides (this information was used to build the quantitative structure activity relationship (QSAR) models). 
